Table 1 Baseline characteristics of patients
Characteristics | Training(n = 229) | Validation(n = 107) |
|---|---|---|
Age (years) | ||
  < 60 | 192(83.8%) | 85(79.4%) |
  ≥ 60 | 37(16.2%) | 22(20.6%) |
Gender | ||
 Male | 153(66.8%) | 72(67.3%) |
 Female | 76(33.2%) | 35(32.7%) |
ECOG score | ||
  < 2 | 168(73.4%) | 75(70.1%) |
  ≥ 2 | 61(26.6%) | 32(29.9%) |
Ann Arbor stages | ||
 I–II | 97(42.4%) | 50(46.7%) |
 III–IV | 132(57.6%) | 57(53.3%) |
B symptoms | 57(24.9%) | 22(20.6%) |
Risk stratification | ||
 Low | 76(33.2%) | 41(38.3%) |
 High | 153(66.8%) | 66(61.7%) |
Bone marrow involved | 36(15.7%) | 16(15%) |
Central nervous system (CNS) involved | 14(6.1%) | 5(4.7%) |
Lymph-node involvement | 111(48.5%) | 49(45.8%) |
Extranodal involvement sites | ||
  < 2 | 122(53.3%) | 63(58.9%) |
  ≥ 2 | 107(46.7%) | 44(41.1%) |
EBV encoded small RNAs (EBERs)(+) | 48(21%) | 28(26.2%) |
 ALB < 40 mg/L | 92(40.2%) | 58(54.2%) |
 CRP ≥ 10 mg/L | 101(43.7%) | 47(43.9%) |
 LDH ≥ 334 U/L | 87(38%) | 43(40.2%) |
 d-NLR ≥ 1.6 | 58(25.3%) | 34(31.8%) |
 PLT < 254 × 109/L | 127(55.5%) | 54(50.5%) |
International Prognostic Indexs (IPI) score ≥ 2 | 137(59.8%) | 61(57%) |
Radiation therapy | 29(12.7%) | 12(11.2%) |
 ASCT | 9(3.9%) | 3(2.8%) |
 CNS prophylaxis | 184(80.3%) | 89(83.2%) |
 Abdominal lesions | 137(59.8%) | 58(54.2%) |
Chemotherapy regimen | ||
 R-CODOX-M | 152(66.4%) | 69(64.5%) |
 R-EPOCH | 25(10.9%) | 8(7.5%) |
 R-CHOP | 28(12.2%) | 15(14%) |
 R-Hyper-CVAD | 17(7.4%) | 12(11.2%) |
 Others | 7(3.1%) | 3(2.8%) |